Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Johnson & Johnson Announces New Collaborations And Seeks Hepatitis B Cure

XTALKS NEWS

Collaboration

The healthcare giant has partnered with China-based Chia Tai Tianqing Pharmaceutical Group, to develop a combination therapy to treat patients with hepatitis B.

Share this!

January 12, 2016 | by Sarah Massey, M.Sc.

In anticipation of the 33rd annual J.P. Morgan Healthcare Conference, Johnson & Johnson will be announcing 21 new collaborations covering experimental disease treatments, medical devices and consumer health products. The healthcare giant has partnered with China-based Chia Tai Tianqing Pharmaceutical Group, to develop a combination therapy to treat patients with hepatitis B.

Johnson & Johnson has also set up a collaboration with Aelix Therapeutics with a focus on developing an HIV vaccine. The company contributed Series A financing to the Spanish biotech, to support development costs for the therapeutic vaccine.

Johnson & Johnson will also enter into a joint venture with ViiV Healthcare to develop better treatment options for patients with HIV, including a long-acting injectable drug designed to replace the pills currently used to manage the disease. The HIV injectable treatment would require only six injections per year.

ViiV Healthcare was created as a joint venture between GlaxoSmithKline and Pfizer in 2009 as a stand-alone company focused on developing HIV therapies. GlaxoSmithKline released a statement last week announcing that their long-acting combination therapy of rilpivirine (RPV LA) and cabotegravir (CAB LA) will be tested in a Phase III clinical trial set to start in mid-2016.



The new medical device deals made by Johnson & Johnson include novel surgical devices – including technologies used to resect tumors – along with devices used to treat atrial fibrillation. Its consumer health offerings have been expanded to include a partnership with the University of Heidelberg in Germany on hair growth products, dental care techniques and new technologies for skin care.

Perhaps the most significant of Johnson & Johnson’s new collaborations is its pact with Chia Tai Tianqing Pharmaceutical Group (CTTQ), a subsidiary of Sino Biopharma. This Chinese drugmaker has set its sights on using research into immune modulating agents to develop a cocktail of therapies that will provide a cure for hepatitis B.

“What we know from HIV and HCV, with chronic viruses, you need a combination therapy,” said Lawrence Blatt, infectious disease chief of Johnson & Johnson. “We're trying to explore direct antivirals, block the life cycle of the virus as well as activating the immune system, so it's a dual approach, immunological and antiviral. We want to marry those two into a functional cure.”

Blatt's previous hepatitis C-focused biotech company, Alios, was acquired by Johnson & Johnson last year for $1.75 billion. “We are looking for the best science no matter where it is,” said Blatt. According to Robert Urban, Boston deals chief for Johnson & Johnson, the company’s four main deal centers in London, Boston, San Francisco and Shanghai, make the drugmaker well-positioned to acquire the best technologies from around the globe, in order to further the company’s research strategy.

Sources:

WATCH & PARTICIPATE IN THESE WEBINARS 


 

Patient-Level Data Sharing in Clinical Research

Cancer Immunotherapy: Advancing and Accelerating Discovery Programs


Keywords: Hepatitis B, Vaccine, Collaboration


| NEXT ARTICLE | MORE NEWS |

Share this with your colleagues!

READ THESE NEXT
Elsevier Launches New Open Access Journal For Clinical Trial Professionals

January 11, 2016 - Elsevier Launches New Open Access Journal For Clinical Trial Professionals


Charles River Announces Acquisition of WIL Research

January 8, 2016 - Early yesterday, contract research organization (CRO) Charles River Laboratories announced they had entered into an agreement to acquire WIL Research for an estimated $585 million


Roche Looks To Assess Arthritis Drug As Possible Treatment For PAH

January 8, 2016 - Swiss drugmaker Roche has formed an alliance with the UK’s Department of Health to conduct a series of clinical trials aimed at determining whether the company’s arthritis biologic, tocilizumab (or Actemra), is effective at treating pulmonary arterial hypertension (PAH).


LEAVE A COMMENT
 
Copyright © 2016-2017 Honeycomb Worldwide Inc.